Usher Iii Initiative , Inc.

Survey findings show 79% of adults with T1D and 83% of caregivers of children under the age of 18 with T1D changed how they lived their life when they first learned of their or their loved one's T1D diagnosis, because they felt overwhelmed and underprepared. 68% of adults with T1D, who did not screen, say they regret not taking an autoantibody test to better understand their risk of developing T1D. SAN MATEO, Calif., June 5, 2024 /PRNewswire/ -- New survey research from Beyond Type 1, a mission-driven organization helping people with diabetes stay alive and thrive, entitled "The Cost of Not Knowing," quantifies the impacts of a type 1 diabetes (T1D) diagnosis among adults over the age of 18 with T1D and caregivers of children under 18 with T1D – with a focus on their emotional, social, and financial health. Among the most notable takeaways, 68% of adults with T1D who were not screened regret not taking an autoantibody test early to understand their risk of developing the disease. This finding is particularly poignant considering nearly 9 in 10 (88%) required emergency care for T1D symptoms before or during their diagnosis. "The Cost of Not Knowing" was commissioned by Sanofi US. Continue Reading View PDF Key Survey Findings "Working for an organization on the frontlines of the fight for T1D awareness, we hear constantly from adults with T1D and caregivers about the significant, oftentimes intangible toll of an unexpected diagnosis," said Kristian Hurley, Senior Vice President of Programs, Advocacy, & Health Equity at Beyond Type 1. "The Cost of Not Knowing' pulls back the curtain on these significant impacts and highlights the value of early detection on a person's financial, social, and emotional health." The Toll of Diagnosis According to the findings, "not knowing" about the risk of developing T1D has its costs – including major emotional, social, and financial burdens: Emotional: 64% of adults with T1D say their emotional health declined when they first received their diagnosis; 61% who experienced feelings such as sadness, fear, anger, or uncertainty at the time of their diagnosis say knowing about their risk sooner would have diminished these feelings. Social: Nearly 9 in 10 caregivers (87%) gave up some of their interests or future plans when they learned of their loved one's diagnosis; this is also true for 71% of adults with T1D when they learned of their own diagnosis. Financial: Half (50%) of adults with T1D spent at least $5,000 on emergency care for their T1D symptoms before or during their diagnosis, with nearly 1 in 4 (24%) spending at least $10,000. The Need for "Knowing" For both adults with T1D and caregivers, early detection has a clear impact, particularly on how they live their life. Notably, 79% of adults with T1D and 83% of caregivers changed how they lived their life when they first learned of their/their loved one's T1D diagnosis because they felt overwhelmed and underprepared. Had they screened and known about their diagnosis sooner, however, 85% of those with T1D say their life may have been different, with more than 1 in 3 (34%) stating they may have felt more in control of their health, 28% stating they may have had more time to prepare, and 20% stating they may have avoided the stress that comes with "not knowing." Award-winning singer, songwriter, actor, entrepreneur, and philanthropist USHER has first-hand experience with the toll of diagnosis through the eyes of a parent, after his child was diagnosed at age six, and has since been vocal about the importance of early T1D screening. Sanofi engaged USHER as a spokesperson for the 1 Pledge Campaign. He's a spokesperson for "The Cost of Not Knowing" and is also part of a contingent that will be speaking with legislators about the importance of early screening on Capitol Hill. "As a parent of a child with T1D, I understand deeply that this diagnosis can turn your world upside down in an instant," USHER said. "I wish – as part of my family's journey – we had known about the availability of early screening and the power it gives to prepare for the future; a year, a month, or even a day of advanced notice would have made all the difference. That's why I believe so strongly about the importance of these findings and am passionate about using my voice and platform to encourage people to get screened early for T1D." Today, over 1.45 million people in the U.S. live with T1D, an autoimmune disease where the immune system attacks insulin-producing cells in the pancreas. T1D can happen to anyone at any age, and ~90% of those diagnosed have no family history. For many individuals and their families, however, a T1D diagnosis comes as a complete shock – with many learning of their condition after experiencing severe symptoms in an emergency setting. While screening for T1D autoantibodies can indicate the risk of developing the condition before symptoms occur, the research confirmed that screening remains an uncommon practice, underscoring the urgency surrounding this new research and the importance of early screening. Perceived Barriers Preventing Access Despite the critical importance of early detection, autoantibody screening remains uncommon, largely due to awareness and perceived access barriers. Just consider that only 14% of adults with T1D say they were screened with an autoantibody test prior to their diagnosis – while 72% of those who did not screen were completely unaware that autoantibody screening was available. Of those who were aware, 40% say that their insurance wouldn't cover the cost and 28% say their healthcare provider did not offer it. Even still, 92% of adults with T1D and 96% of caregivers say they would recommend friends and family members get an early autoantibody test for T1D to understand their risk of developing the disease. Beyond Type 1 and USHER will share more about these findings at a Summit in Washington, D.C. on June 12, hosted by Sanofi. Key takeaways of "The Cost of Not Knowing" can be found here: . USHER is a paid spokesperson for Sanofi. Research Methodology This research was conducted by Wakefield Research () via two survey instruments—one among 1,000 US adults with type 1 diabetes and a second among 1,000 US caregivers to children under the age of 18 with type 1 diabetes, between March 15th and March 29th, 2024, using an email invitation and an online survey. Results of any sample are subject to sampling variation. The magnitude of the variation is measurable and is affected by the number of interviews and the level of the percentages expressing the results. For the interviews conducted in this particular study, the chances are 95 in 100 that a survey result does not vary, plus or minus, by more than 3.1 percentage points from the result that would be obtained if interviews had been conducted with all persons in the universe represented by the sample. The distribution of key demographic characteristics for both audiences, such as gender and age, was monitored during data collection, to align with available information provided by the CDC and NIH. About Beyond Type 1 Founded in 2015, Beyond Type 1 is a global nonprofit dedicated to the diabetes community. The organization serves the largest digital audience of any diabetes nonprofit with the mission to help people living with diabetes stay alive and thrive. Through peer support programs, global campaigns and digital platforms, Beyond Type 1 is uniting the global diabetes community—across all types of diabetes—and helping to change what it means to live with chronic illness. In 2019, the organization launched its Beyond Type 2 community, dedicated to those living with type 2 diabetes. For more information, visit beyondtype1.org or beyondtype2.org. About Wakefield Research Wakefield Research is a leading, independent provider of quantitative, qualitative, and hybrid market research for thought leadership and strategic insights. Wakefield Research is a partner to the world's leading brands and agencies, including 50 of the Fortune 100. We conduct research in nearly 100 countries and our surveys appear regularly in top-tier media. For more information, please visit . Contact: Oluwatona Campbell, [email protected] SOURCE Beyond Type 1

A new biotech company has formed to develop a potential gene therapy for a rare, inherited disorder that leads to skin so fragile that it tears as easily as paper. Telaria is the latest company unveiled by Replay, which itself is a new gene therapy biotech. Launched earlier this year, Replay operates a “hub-and-spoke” business model in which it develops its own platform technologies and identifies therapeutic areas that can be addressed by one or more of these technologies. Replay, which maintains operations in San Diego and London, then forms companies focused on particular therapeutic areas. Rare skin diseases are the focus of Telaria. The company’s Telaria’s lead program is being developed for recessive dystrophic epidermolysis bullosa (RDEB), an inherited disorder in which genetic mutations block or disrupt the formation of collagen that connects the epidermis to the dermis. Absent the connections between these layers, the skin becomes easily susceptible to wounds and blistering. There are no FDA-approved therapies for the disorder. Treatment is mainly supportive care. Compared to another type of the disorder called dominant dystrophic epidermolysis bullosa, RDEB is more severe and can lead to scarring, severe pain, and problems in internal organs. Complications that can stem from RDEB include chronic inflammation and squamous cell carcinoma, a type of skin cancer. Like other Replay companies, Telaria will leverage the larger capacity of the herpes simplex virus (HSV) to deliver a gene therapy. The adeno associated-viruses (AAV) frequently used for genetic medicines delivery have limited capacity for their genetic cargos. Replay has engineered a version of HSV that it claims is capable delivering up to eight times the payload capacity of AAV vectors. That capacity enables Replay to consider genes that are too big for AAV-based delivery. The company is aiming for even bigger genes. It is developing an HSV vector that could deliver up to 30 times the payload of AAV. “There is currently no approved cure for individuals suffering from RDEB and I am aware, from my own personal experience, that the current standard of care is limited and does not provide long-term and sustainable benefit to patients,” Telaria co-founder Alexander Silver said in a prepared statement. “Replay’s synHSV technology, which enables the delivery of big DNA to the skin through its differentiated payload capacity, has the potential to disrupt the genetic skin disease gene therapy field, and to bring much needed treatments to patients as rapidly and safely as possible.” Telaria joins a small field of companies pursuing epidermolysis bullosa treatments. Krystal Biotech developed B-VEC, a topical and redosable gene therapy designed to deliver two copies of the COL7A1 gene, which encodes a protein key to collagen formation. The Pittsburgh-based company’s gene therapy is currently under FDA review; a regulatory decision is expected by late February. Abeona Therapeutics is developing an RDEB cell therapy called EB-101. Earlier this month, the New York-based biotech reported positive Phase 3 data, paving the way for plans to submit a biologics license application with the FDA. Amicus Therapeutics entered the epidermolysis bullosa chase in 2015 with the acquisition of Scioderm, a biotech developing a wound-healing topical drug. But Amicus ended up stopping development of that program two years later following the failure of a Phase 3 clinical trial. Replay launched in July backed by $55 million in seed financing led by KKR & Co. and OMX Ventures. Telaria is the second Replay company unveiled this year, following the launch last month of retinal eye disease biotech Eudora. That company is developing gene therapies for retinitis pigmentosa, Stargardt disease, and Usher syndrome type 1B. Public domain photo by the CDC

ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022Company plans to discuss findings from sepofarsen Illuminate trial with regulators and provide an update in Q3/early Q4; Enrollment is ongoing in Sirius, a Phase 2/3 trial of ultevursen (QR-421a), for USH2A-mediated Usher syndrome and retinitis pigmentosaCash runway into 2025 LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today reported its financial and operating results for the second quarter ended June 30, 2022, and provided a business update. Business Operations and Program Updates Program updates In Q3, the Company plans to engage with the EMA and FDA to discuss these data from the Illuminate trial. Following this interaction, ProQR will share an update in Q3 or early Q4, depending on timing of regulatory meetings. The Company plans to discuss the regulatory path for ultevursen with the EMA and FDA. Enrollment is ongoing in Sirius, a Phase 2/3 trial of ultevursen (QR-421a), for USH2A-mediated Usher syndrome and retinitis pigmentosa.ProQR is accelerating the development of its Axiomer RNA editing platform and pipeline activities, including focusing on initially liver and CNS therapeutic areas, which have strong alignment with ProQR’s oligonucleotide delivery approaches. The Company will present further non-clinical data for Axiomer and announce its internal development targets in H2 2022.In May, the Company presented its proprietary RNA base-editing Axiomer technology at the Oligonucleotide and Peptide Therapeutics conference (TIDES USA). Business updates In conjunction with the Annual General Meeting held in June, ProQR announced several leadership updates: René Beukema has joined the management team as Chief Corporate Development Officer and General Counsel and was elected to the Management Board.Gerard Platenburg has assumed the Chief Scientific Officer role, with leadership oversight of the Axiomer RNA-editing platform technology.John Maraganore, PhD, former Founding CEO of Alnylam Pharmaceuticals, extended his commitment as a strategic advisor to the Supervisory Board.Smital Shah, Chief Business and Financial Officer, will leave the Company as part of a planned transition at the end of 2022. A search has been initiated for a new Chief Financial Officer. Financial Highlights On June 30, 2022, ProQR held cash and cash equivalents of €156.4 million, compared to €187.5 million on December 31, 2021. Net cash used in operating activities during the three-month period ended June 30, 2022 was €14.8 million, compared to €10.0 million for the same period last year. Research and development costs were €11.4 million for the quarter ended June 30, 2022 compared to €9.7 million for the same period last year. General and administrative costs were €5.4 million for the quarter ended June 30, 2022 compared to €4.1 million for the quarter ended June 30, 2021. Net loss for the three-month period ended June 30, 2022 was €14.7 million, or €0.21 per diluted share, compared to €15.8 million, or €0.24 per diluted share, for the same period last year. For further financial information for the period ending June 30, 2022, please refer to the financial statements appearing at the end of this release. About Leber Congenital Amaurosis 10 (LCA10) Leber congenital amaurosis (LCA) is the most common cause of blindness due to genetic disease in children. It consists of a group of diseases of which LCA10 is the most frequent and one of the most severe forms. LCA10 is caused by mutations in the CEP290 gene, of which the c.2991+1655A>G (p.Cys998X) mutation has the highest prevalence. LCA10 leads to early loss of vision causing most people to lose their sight in the first few years of life. To date, there are no treatments approved that treat the underlying cause of the disease. Approximately 2,000 people in the Western world have LCA10 because of this mutation. About sepofarsen Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital amaurosis 10 due to the c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene. The mutation leads to aberrant splicing of the mRNA and non-functional CEP290 protein. Sepofarsen is designed to enable normal splicing, resulting in restoration of normal (wild type) CEP290 mRNA and subsequent production of functional CEP290 protein. Sepofarsen is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in the United States and the European Union and received fast-track designation and rare pediatric disease designation from the FDA as well as access to the PRIME scheme by the EMA. About Usher syndrome type 2a and retinitis pigmentosa Usher syndrome is the leading cause of combined deafness and blindness. People with Usher syndrome type 2a are usually born with hearing loss and start to have progressive vision loss during adulthood. The vision loss can also occur without hearing loss in a disease called non-syndromic retinitis pigmentosa. Usher syndrome type 2a and non-syndromic retinitis pigmentosa can be caused by mutations in the USH2A gene. To date, there are no pharmaceutical treatments approved or in clinical development that treat the vision loss associated with mutations in USH2A. About ultevursen Ultevursen (formerly QR-421a) is a first-in-class investigational RNA therapy designed to address the underlying cause of vision loss in Usher syndrome type 2a and non-syndromic retinitis pigmentosa due to mutations in exon 13 of the USH2A gene. QR-421a is designed to restore functional usherin protein by using an exon skipping approach with the aim to stop or reverse vision loss in patients. Ultevursen is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in the US and the European Union and received fast-track and rare pediatric disease designations from the FDA. About Axiomer® technology ProQR is pioneering a next-generation RNA technology called Axiomer®, which could potentially yield a new class of medicines for genetic diseases. Axiomer “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells. The Axiomer EONs are designed to recruit an endogenously expressed RNA editing system called ADAR, which can direct the change of an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G). About ProQR ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer®, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for genetic diseases. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Learn more about ProQR at www.proqr.com. FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our product candidates, including sepofarsen (QR-110) and the clinical development and the therapeutic potential thereof, statements regarding ultevursen (QR-421a) and the clinical development and therapeutic potential thereof, statements regarding our pipeline of programs targeting inherited retinal dystrophies, the potential of our technologies and platforms (including Axiomer®), our other programs and business operations, our current and planned partnerships and collaborators and the intended benefits thereof, our planned interactions with regulatory authorities relating to our programs, our updated strategic plans and the intended benefits thereof, and our financial position and cash runway. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted by the ongoing COVID-19 pandemic; the likelihood of our clinical programs being executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for later data to alter initial and preliminary results of early-stage clinical trials, including as a result of differences in the trial designs and protocols across different trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the outcomes of our planned interactions with regulatory authorities; the ability to secure, maintain and realize the intended benefits of collaborations with partners; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; our ability to maintain and service our loan facility with Pontifax and Kreos; the possibility that we will not be able to regain compliance with Nasdaq’s Minimum Bid Price Requirement, secure a second period of 180 days to regain compliance, or maintain compliance with any of the other Nasdaq continued listing requirements. general business, operational, financial and accounting risks; and risks related to litigation and disputes with third parties. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law. Cautionary note on future updates The statements contained in this press release reflect our current views with respect to future events, which may change significantly as the global consequences of the ongoing COVID-19 pandemic rapidly develop. Accordingly, we do not undertake and specifically disclaim any obligation to update any forward-looking statements. ProQR Therapeutics N.V. Investor contact:Sarah KielyProQR Therapeutics N.V.T: +1 617 599 6228skiely@proqr.comorHans VitzthumLifeSci AdvisorsT: +1 617 430 7578hans@lifesciadvisors.com Media contact:Robert StanislaroFTI ConsultingT: +1 212 850 5657robert.stanislaro@fticonsulting.com PROQR THERAPEUTICS N.V.Unaudited Condensed Consolidated Statement of Financial Position June 30, December 31, 2022 2021 € 1,000 € 1,000Assets Current assets Cash and cash equivalents 156,402 187,524 Prepayments and other receivables 4,159 3,404 Other taxes 498 555 Total current assets 161,059 191,483 Property, plant and equipment 17,373 17,467 Investments in associates — 8 Investments in financial assets 621 621 Total assets 179,053 209,579 Equity and liabilities Equity Equity attributable to owners of the Company 87,369 113,833 Non-controlling interests (395) (604)Total equity 86,974 113,229 Current liabilities Borrowings 7,214 4,771 Lease liabilities 1,378 1,534 Derivative financial instruments 228 3,995 Trade payables 767 191 Current income tax liability — — Social securities and other taxes 1,195 1,230 Deferred income 6,824 5,115 Other current liabilities 9,533 10,760 Total current liabilities 27,139 27,596 Borrowings 37,777 39,319 Lease liabilities 14,563 14,748 Deferred income 12,600 14,687 Total liabilities 92,079 96,350 Total equity and liabilities 179,053 209,579 PROQR THERAPEUTICS N.V.Unaudited Condensed Consolidated Statement of Profit or Loss and OCI (€ in thousands, except share and per share data) Three month period Six month period ended June 30, ended June 30, 2022 2021 2022 2021 € 1,000 € 1,000 € 1,000 € 1,000Revenue 1,025 243 2,259 243 Other income 99 411 200 552 Research and development costs (11,449) (9,735) (24,816) (18,640)General and administrative costs (5,412) (4,122) (10,320) (7,461)Total operating costs (16,861) (13,857) (35,136) (26,101) Operating result (15,737) (13,203) (32,677) (25,306)Finance income and expense (119) (2,464) (1,378) (2,757)Results related to associates — — (8) — Gain on disposal of associate — — — 514 Gain on derecognition of financial liabilities 1,144 — 1,144 — Results related to financial liabilities measured at fair value through profit or loss 62 (33) 3,826 (762) Result before corporate income taxes (14,650) (15,700) (29,093) (28,311)Income taxes (20) (53) (27) (60) Result for the period (14,670) (15,753) (29,120) (28,371)Other comprehensive income (foreign exchange differences on foreign operation) 689 (141) 911 255 Total comprehensive income (13,981) (15,894) (28,209) (28,116) Result attributable to Owners of the Company (14,887) (15,746) (29,329) (28,353)Non-controlling interests 217 (7) 209 (18) (14,670) (15,753) (29,120) (28,371)Total comprehensive income attributable to Owners of the Company (14,198) (15,887) (28,418) (28,098)Non-controlling interests 217 (7) 209 (18) (13,981) (15,894) (28,209) (28,116) Share information Weighted average number of shares outstanding1 71,362,088 66,147,153 71,359,642 58,521,508 Earnings per share attributable to owners of the Company (Euro per share) Basic loss per share1 (0.21) (0.24) (0.41) (0.48)Diluted loss per share1 (0.21) (0.24) (0.41) (0.48) For these periods the potential exercise of share options is not included in the diluted earnings per share as the Company was loss-making. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal.PROQR THERAPEUTICS N.V.Unaudited Condensed Consolidated Statement of Changes in Equity Attributable to owners of the Company Numberof shares ShareCapital SharePremium Equity settledEmployeeBenefitReserve Option premium onconvertibleloan TranslationReserve AccumulatedDeficit Total Non-controllinginterests TotalEquity € 1,000 € 1,000 € 1,000 € 1,000 € 1,000 € 1,000 € 1,000 € 1,000 € 1,000Balance at January 1, 2021 54,131,553 2,165 288,757 23,825 280 (189) (257,747) 57,091 (545) 56,546 Result for the period — — — — — — (28,353) (28,353) (18) (28,371)Other comprehensive income — — — — — 255 — 255 — 255 Recognition of share-based payments 112,657 5 382 2,719 — — — 3,106 — 3,106 Issuance of ordinary shares 16,508,475 660 84,594 — — — — 85,254 — 85,254 Treasury shares transferred (127,303) — — — — — — — — — Share options lapsed — — — (160) — — 160 — — — Share options exercised 243,189 — 753 (541) — — 541 753 — 753 Balance at June 30, 2021 70,868,571 2,830 374,486 25,843 280 66 (285,399) 118,106 (563) 117,543 Balance at January 1, 2022 74,865,381 2,995 398,309 28,443 1,426 430 (317,770) 113,833 (604) 113,229 Result for the period — — — — — — (29,329) (29,329) 209 (29,120)Other comprehensive income — — — — — 911 — 911 — 911 Recognition of share-based payments — — — 1,921 — — — 1,921 — 1,921 Issuance of ordinary shares — — — — — — — — — — Treasury shares transferred (71,283) — — — — — — — — — Share options lapsed — — — (380) — — 380 — — — Share options exercised / RSUs vested 71,283 — 33 (256) — — 256 33 — 33 Balance at June 30, 2022 74,865,381 2,995 398,342 29,728 1,426 1,341 (346,463) 87,369 (395) 86,974 PROQR THERAPEUTICS N.V.Unaudited Condensed Consolidated Statement of Cash Flows Three month period Six month period ended June 30, ended June 30, 2022 2021 2022 2021 € 1,000 € 1,000 € 1,000 € 1,000Cash flows from operating activities Net result (14,670) (15,753) (29,120) (28,371)Adjustments for: — Depreciation 591 602 1,161 1,233 — Share-based compensation 738 1,471 1,921 2,719 — Financial income and expenses 120 2,464 1,378 2,757 — Results related to associates — — 8 — — Gain on disposal of associate — — — (514)— Results related to financial liabilities measured at fair value through profit or loss (62) 33 (3,826) 762 — Gain on derecognition of financial liabilities (1,144) — (1,144) — — Income tax expenses 20 53 27 60 Changes in working capital 820 1,774 (3,234) 822 Cash used in operations (13,587) (9,356) (32,829) (20,532) Corporate income tax paid (20) (53) (27) (60)Interest received — 5 — 5 Interest paid (1,237) (575) (2,455) (1,153) Net cash used in operating activities (14,844) (9,979) (35,311) (21,740) Cash flow from investing activities Purchases of property, plant and equipment (231) (52) (475) (84) Net cash used in investing activities (231) (52) (475) (84) Cash flow from financing activities Proceeds from issuance of shares, net of transaction costs — 82,601 — 85,254 Proceeds from exercise of share options — 185 33 753 Proceeds from borrowings — 569 — 569 Proceeds from convertible loans — — — — Repayment of lease liability (357) (14) (933) (250) Net cash (used in)/generated by financing activities (357) 83,341 (900) 86,326 Net increase (decrease) in cash and cash equivalents (15,432) 73,310 (36,686) 64,502 Currency effect cash and cash equivalents 4,222 (1,746) 5,564 (898)Cash and cash equivalents, at beginning of the period 167,612 67,878 187,524 75,838 Cash and cash equivalents at the end of the period 156,402 139,442 156,402 139,442